Skip to main content

ChEMBL 20 coming soon...

By

Happy New Year for 2015 from the ChEMBL group!

Release 20 of the ChEMBL database will be happening around the end of the month, and for those who can't wait, here's a preview of the exciting new features you can expect to find there:

  • HELM notation - we have developed an implementation of the Pistoia Alliance's HELM standard for biotherapeutics and will be supplying HELM notation for just under 20K peptides (previously represented by mol files). We will also make our monomer library available in case others wish to use it to generate their own HELM notation.
  • Structural alerts - in place of the old 'Med Chem Friendly' flag used in ChEMBL, we now have an extensive set of structural alerts calculated for the ChEMBL compounds. The data set includes eight different sets of alerts (including sets published by Pfizer, Glaxo, BMS, University of Dundee, NIH MLSMR and PAINS filters) providing more than 1100 distinct SMARTS. Alerts found for a given compound can be viewed on the interface and the full data set will be included in the database downloads.
  • Cell Report Cards - we will now provide ChEMBL IDs and Report Card pages for cells and cell-lines, as well as a keyword search facility. This will enable users to quickly identify all assays that have been performed in a particular cell-line and will also provide cross references to other resources such as the LINCS project.
  • HRAC/FRAC/IRAC classification - for known herbicides, fungicides and insecticides, we provide their classification according to HRAC/FRAC/IRAC. This gives an indication of the mechanism of action of each compound. The classification can be found on the compound report card for these crop protection chemicals.
  • New bioactivity data - in addition to the usual updates of bioactivity data from scientific literature and PubChem BioAssay we have 12 new sets of screening results from the MMV Malaria Box and an extensive set of in vitro DMPK and physiochemical property data for more than 5,700 publicly disclosed drugs and compounds deposited by AstraZeneca.
  • There will be some schema changes to incorporate these new features, but these will be additions and are unlikely to break existing code.
Watch this space!


The ChEMBL Team
Labels:

Comments

Samo said…
Will you make the SMARTS patterns freely available?
7 January 2015 at 08:46
christian_l said…
How soon after that are you planning to release myChEMBL 20?

I'm also very interested in the SMARTS patterns!
7 January 2015 at 18:28
Anna said…
Yes, the SMARTS will be available in the database downloads.
20 January 2015 at 07:52
Post a Comment

Popular posts from this blog

ChEMBL 34 is out!

By
We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.
Post a Comment
Read more

New SureChEMBL announcement

By
(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f
Post a Comment
Read more

Accessing SureChEMBL data in bulk

By
It is the peak of the summer (at least in this hemisphere) and many of our readers/users will be on holiday, perhaps on an island enjoying the sea. Luckily, for the rest of us there is still the 'sea' of SureChEMBL data that awaits to be enjoyed and explored for hidden 'treasures' (let me know if I pushed this analogy too far). See here and  here for a reminder of SureChEMBL is and what it does.  This wealth of (big) data can be accessed via the SureChEMBL interface , where users can submit quite sophisticated and granular queries by combining: i) Lucene fields against full-text and bibliographic metadata and ii) advanced structure query features against the annotated compound corpus. Examples of such queries will be the topic of a future post. Once the search results are back, users can browse through and export the chemistry from the patent(s) of interest. In addition to this functionality, we've been receiving user requests for  local (behind the
Post a Comment
Read more

New Drug Approvals - Pt. XVII - Telavancin (Vibativ)

By jpo
The latest new drug approval, on 11th September 2009 was Telavancin - which was approved for the treatment of adults with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria , including Staphylococcus aureus , both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains. Telavancin is also active against Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus anginosus group (includes S. anginosus, S. intermedius and S. constellatus ) and Enterococcus faecalis (vancomycin susceptible isolates only). Telavancin is a semisynthetic derivative of Vancomycin. Vancomycin itself is a natural product drug, isolated originally from soil samples in Borneo, and is produced by controlled fermentation of Amycolatopsis orientalis - a member of the Actinobacteria . Telavancin has a dual mechanism of action, firstly it inhibits bacterial cell wall synthesis by interfering with the polymerization and cross-linking of peptid
Post a Comment
Read more

A python client for accessing ChEMBL web services

By
Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEMBL d
1 comment
Read more